[{"address1": "15 Crosby Drive", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 357 4000", "website": "https://www.ocutx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 325, "companyOfficers": [{"maxAge": 1, "name": "Dr. Pravin U. Dugel M.D.", "age": 61, "title": "Executive Chairman, President & CEO", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 1487392, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey S. Heier M.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 676550, "exercisedValue": 0, "unexercisedValue": 458979}, {"maxAge": 1, "name": "Dr. Peter K. Kaiser M.D.", "age": 58, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 698866, "exercisedValue": 0, "unexercisedValue": 669070}, {"maxAge": 1, "name": "Mr. Jason  Robins", "age": 48, "title": "Senior VP of Finance, Interim CFO & Principal Accounting Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Jarrett Ph.D.", "age": 68, "title": "Chief Technical Officer", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William S. Slattery Jr.", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Todd D.C. Anderman J.D.", "age": 43, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William H. Ransone II", "title": "Vice President of Global Sales & Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Rubenstein M.S.", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Donald  Notman Jr.", "title": "CFO, COO & Principal Accounting Officer (Leave of Absence)", "fiscalYear": 2024, "totalPay": 679770, "exercisedValue": 0, "unexercisedValue": 90888}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 9.06, "open": 9.17, "dayLow": 8.83, "dayHigh": 9.34, "regularMarketPreviousClose": 9.06, "regularMarketOpen": 9.17, "regularMarketDayLow": 8.83, "regularMarketDayHigh": 9.34, "payoutRatio": 0.0, "beta": 0.9, "forwardPE": -7.118237, "volume": 2622038, "regularMarketVolume": 2622038, "averageVolume": 4343890, "averageVolume10days": 4980650, "averageDailyVolume10Day": 4980650, "bid": 6.62, "ask": 11.37, "bidSize": 2, "askSize": 2, "marketCap": 1933102976, "fiftyTwoWeekLow": 5.785, "fiftyTwoWeekHigh": 16.44, "allTimeHigh": 44.19, "allTimeLow": 1.995, "priceToSalesTrailing12Months": 37.21012, "fiftyDayAverage": 11.5462, "twoHundredDayAverage": 10.958975, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1273010944, "profitMargins": 0.0, "floatShares": 202681931, "sharesOutstanding": 217691779, "sharesShort": 11506830, "sharesShortPriorMonth": 12345939, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0533, "heldPercentInsiders": 0.02814, "heldPercentInstitutions": 0.92670995, "shortRatio": 2.33, "shortPercentOfFloat": 0.0535, "impliedSharesOutstanding": 217691779, "bookValue": 3.03, "priceToBook": 2.9306931, "lastFiscalYearEnd": 1767139200, "nextFiscalYearEnd": 1798675200, "mostRecentQuarter": 1767139200, "netIncomeToCommon": -265939008, "trailingEps": -1.42, "forwardEps": -1.2475, "enterpriseToRevenue": 24.504, "enterpriseToEbitda": -4.791, "52WeekChange": 0.23333335, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 8.88, "targetHighPrice": 31.0, "targetLowPrice": 20.0, "targetMeanPrice": 25.58333, "targetMedianPrice": 26.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 737059968, "totalCashPerShare": 3.386, "ebitda": -265694000, "totalDebt": 76968000, "quickRatio": 15.111, "currentRatio": 15.394, "totalRevenue": 51951000, "debtToEquity": 11.763, "revenuePerShare": 0.277, "returnOnAssets": -0.26661, "returnOnEquity": -0.54852, "grossProfits": -151719008, "freeCashflow": -128276496, "operatingCashflow": -204883008, "revenueGrowth": -0.224, "grossMargins": -2.92043, "ebitdaMargins": 0.0, "operatingMargins": -5.26491, "financialCurrency": "USD", "symbol": "OCUL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Ocular Therapeutix, Inc.", "longName": "Ocular Therapeutix, Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1771030792, "regularMarketTime": 1771016400, "exchange": "NGM", "messageBoardId": "finmb_41955650", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -1.98676, "regularMarketPrice": 8.88, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1406295000000, "postMarketChangePercent": 25.649769, "postMarketPrice": 11.1577, "postMarketChange": 2.2776995, "regularMarketChange": -0.18, "regularMarketDayRange": "8.83 - 9.34", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 4343890, "fiftyTwoWeekLowChange": 3.0950003, "fiftyTwoWeekLowChangePercent": 0.5350044, "fiftyTwoWeekRange": "5.785 - 16.44", "fiftyTwoWeekHighChange": -7.5600004, "fiftyTwoWeekHighChangePercent": -0.45985404, "fiftyTwoWeekChangePercent": 23.333336, "earningsTimestamp": 1770298200, "earningsTimestampStart": 1777987800, "earningsTimestampEnd": 1777987800, "earningsCallTimestampStart": 1762261200, "earningsCallTimestampEnd": 1762261200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.42, "epsForward": -1.2475, "epsCurrentYear": -1.30333, "priceEpsCurrentYear": -6.813317, "fiftyDayAverageChange": -2.6661997, "fiftyDayAverageChangePercent": -0.23091577, "twoHundredDayAverageChange": -2.0789747, "twoHundredDayAverageChangePercent": -0.18970522, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "Ocular Therapeutix", "trailingPegRatio": null, "__fetch_time": "2026-02-14"}]